Definition

A preparation of autologous monocytes genetically modified with mRNA technology to express a chimeric antigen receptor (CAR) specific for CD5, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD5 CAR monocytes MT-101 specifically recognize and bind to CD5-expressing tumor cells, and expose the immune system to the CD5 glycoprotein. This may elicit a cytotoxic T-lymphocyte (CTL) response against CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T cells and overexpressed on various B- and T-cell malignancies.